Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

Disclosed are an electrolyte solution for a lithium secondary battery capable of improving the output and lifespan characteristics at high temperature of a lithium secondary battery, and a lithium secondary battery including the same. The electrolyte solution includes a lithium salt, a solvent, and a functional additive. The functional additive includes benzo[d]thiazol-6-yl(fluorosulfonyl)sulfamoyl fluoride.

Disclosed are an electrolyte solution for a lithium secondary battery capable of improving the output and lifespan characteristics at high temperature of a lithium secondary battery, and a lithium secondary battery including the same. The electrolyte solution includes a lithium salt, a solvent, and a functional additive. The functional additive includes benzo[d]thiazol-6-yl(fluorosulfonyl)sulfamoyl fluoride.

The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below:

##STR00001##

The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below:

##STR00001##

The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below:

##STR00001##

The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below:

##STR00001##

A compound of formula (I)

##STR00001##

wherein R, R.sup.1, R.sup.2, R.sup.3, Y, Y.sup.1, a, X, and Z are as defined herein.

The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

The present application discloses an arylamine organic compound and the use thereof. The arylamine organic compound has a structure as shown in general formula (1).

##STR00001##

The arylamine organic compound has a relatively high glass transition temperature, a relatively high thermal stability, a relatively small visible light extinction coefficient, and a relatively high refractive index; and when the arylamine organic compound is used as a capping layer material for an organic electronic device, the visible luminous efficiency of the organic electronic device can be effectively improved.